Literature DB >> 2844685

Opioid-induced modification of granulocyte function.

M Marcoli1, G Ricevuti, A Mazzone, M Bekkering, S Lecchini, G M Frigo.   

Abstract

Inhibition of human granulocyte chemotaxis towards casein was observed in the presence of both the mu and kappa opioid receptor agonists, which, per se, exhibited chemokinetic activity. Naloxone was found to prevent both the opioid-related and opioid-unrelated increase in granulocyte migration. Moreover, morphine inhibited the aggregation response of granulocytes in a naloxone-sensitive way, while the opioid peptides were ineffective. Although opioid agonists with different receptor specificity were capable of strongly modifying human granulocyte migration, no conclusion can be drawn on the role of opioid receptors in regulating migrating activity. On the other hand, opioid receptor activation by morphine is likely to be responsible for aggregation inhibition.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2844685     DOI: 10.1016/0192-0561(88)90129-4

Source DB:  PubMed          Journal:  Int J Immunopharmacol        ISSN: 0192-0561


  4 in total

1.  Interaction between morphine and granulocyte aggregation in myocardial ischaemia.

Authors:  A Mazzone; G Ricevuti
Journal:  Cardiovasc Drugs Ther       Date:  1990-02       Impact factor: 3.727

2.  Morphine-induced enhancement in the granulocyte response to thioglycollate administration in the rat.

Authors:  Karamarie Fecho; Donald T Lysle
Journal:  Inflammation       Date:  2002-12       Impact factor: 4.092

3.  Peptide opioids and morphine effects on inflammatory process.

Authors:  A Mazzone; G Ricevuti; D Pasotti; A Fioravanti; M Marcoli; S Lecchini; A Notario; G M Frigo
Journal:  Inflammation       Date:  1990-12       Impact factor: 4.092

4.  The opioid peptide dynorphin A induces leukocyte responses via integrin Mac-1 (αMβ2, CD11b/CD18).

Authors:  Nataly P Podolnikova; Julie A Brothwell; Tatiana P Ugarova
Journal:  Mol Pain       Date:  2015-06-03       Impact factor: 3.395

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.